Conversation with The Cancer Letter Clearing the path for MRD as early endpoint in multiple myeloma April 26, 2024Vol.50 No.17By Jacquelyn Cobb
Drugs & Targets FDA approves Anktiva for non-muscle-invasive bladder cancer April 26, 2024Vol.50 No.17
Drugs & Targets FDA revises industry guidance on biologics promotion and advertising April 26, 2024Vol.50 No.17
Funding Opportunities FDA offers funding for meetings on medical policy activities April 19, 2024Vol.50 No.16
Drugs & Targets FDA approves Alecensa for ALK-positive early-stage lung cancer April 19, 2024Vol.50 No.16
Drugs & Targets FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors April 12, 2024Vol.50 No.15
White House White House misses deadline to finalize FDA rule banning menthol cigarettes, prompting lawsuit from health groups April 05, 2024Vol.50 No.14By Jacquelyn Cobb
Regulatory News Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials March 29, 2024Vol.50 No.13By Paul Goldberg
